{"id":"W4411026697","doi":"10.1200/jco.2025.43.17_suppl.lba1005","title":"A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Western University; Hôpital du Saint-Sacrement; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; Royal Victoria Regional Health Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Fulvestrant; Medicine; Estrogen receptor; HER2 negative; Metastatic breast cancer; Palbociclib; Placebo; Internal medicine; Double blind; Cyclin-dependent kinase; Breast cancer; Oncology; Estrogen; Cancer; Pathology; Cell cycle","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003282555,0.0004416169,0.004224578,0.0002001615,0.0002213641,0.00002949157,0.0001107445,0.0002901917,0.00001919378],"category_scores_gemma":[0.00174318,0.0002312754,0.0006678665,0.0001577685,0.0006376636,0.0001879592,0.00006763983,0.000569266,3.210586e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002465197,"about_ca_system_score_gemma":0.001271715,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001094984,"about_ca_topic_score_gemma":0.0001592057,"domain_scores_codex":[0.9949916,0.0009203507,0.00285658,0.0004989058,0.0004080112,0.000324531],"domain_scores_gemma":[0.9865751,0.01005834,0.002365013,0.000239458,0.0004167291,0.000345316],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8485302,0.007147925,0.0003856775,0.00004722828,0.004148268,0.0001091697,0.0007370357,0.00002134159,0.000507522,0.00002932267,0.00004595315,0.1382904],"study_design_scores_gemma":[0.9298418,0.05985537,0.0003809944,0.00113696,0.003960724,0.00009895649,0.001151941,0.0001059327,0.002227336,0.0001725881,0.0008934157,0.0001739977],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9752631,0.002644585,0.0001026079,0.009611108,0.0009805837,0.01112926,0.0002229185,0.00001311328,0.00003271627],"genre_scores_gemma":[0.9950883,0.001317882,0.001132787,0.0003445216,0.0009848318,0.0009727252,0.00002165425,0.00003333096,0.0001039749],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1381164,"threshold_uncertainty_score":0.9431137,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05781636090479739,"score_gpt":0.4786090012652857,"score_spread":0.4207926403604882,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}